Medincell

Medincell ROE

The Return on Equity (ROE) of Medincell (MEDCL.PA) as of Nov 16, 2026 is -1,021.12 %. In the previous year, Return on Equity (ROE) was 112.65 % — a change of -1,006.42% (lower).

ROE

-1,021.12 %

YoY

-1,006.42%

Last updated:

In 2026, Medincell's return on equity (ROE) was -1,021.12 %, a -1,006.42% increase from the 112.65 % ROE in the previous year.

The Medincell ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
-315.35 EUR
Jan 1, 2020
149.86 EUR
Jan 1, 2021
-213.32 EUR
Jan 1, 2022
185.52 EUR
Jan 1, 2023
75.68 EUR
Jan 1, 2024
61.33 EUR
Jan 1, 2025
112.65 EUR
Jan 1, 2026
-1,021.12 EUR
The Medincell ROE history
YEARROEYoY
-1,021.12 %-1,006.42%
112.65 %+83.68%
61.33 %-18.96%
75.68 %-59.20%
185.52 %-186.97%
-213.32 %-242.35%
149.86 %-147.52%
-315.35 %-488.23%
81.23 %-46.81%
152.70 %+204.42%
50.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medincell Stock analysis

What does Medincell do? Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell is one of the most popular companies on Eulerpool.

ROE Details

Decoding Medincell's Return on Equity (ROE)

Medincell's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Medincell's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Medincell's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Medincell’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Medincell stock

Return on Equity (ROE) of Medincell is -1,021.12 % in 2026.

Return on Equity (ROE) of Medincell changed from 112.65 % to -1,021.12 %, representing a -1,006.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Medincell since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Medincell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medincell

All Key Metrics — Medincell